1334298-90-6

Basic information

• Product Name: INCB39110
• Synonyms: Itacitinib;INCB039110;1-[1-[[3-Fluoro-2-(trifluoromethyl)-4-pyridinyl]carbonyl]-4-piperidinyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile;2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)i;INCB039110, Itacitinib
• CAS NO: 1334298-90-6
• Molecular Formula: C26H23F4N9O
• Molecular Weight: 553.53
• Product Categories: API
• Mol File: 1334298-90-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.57±0.1 g/cm3(Predicted)
• PKA: 11.66±0.50(Predicted)
• CAS DataBase Reference: INCB39110(CAS DataBase Reference)
• NIST Chemistry Reference: INCB39110(1334298-90-6)
• EPA Substance Registry System: INCB39110(1334298-90-6)

Safety Data

• Hazardous Substances Data: 1334298-90-6(Hazardous Substances Data)

Usage

Uses

Itacitinib is an orally bioactive inhibitor of Janus-associated kinase 1 with potential antineoplastic activity.

Upstream product

• 52133-67-2 ethyl 2-cyano-4,4-diethoxybutyrate 
• 945950-37-8 4-methyl-7H-pyrrazolo[2,3-d]pyrimidine 
• 7400-06-8 4-amino-6-hydroxy-5-(2,2-diethoxyethyl)pyrimidine 
• 479633-63-1 4-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 90213-66-4 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine 
• 3680-71-5 Allopurinol 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 1314910-43-4 2-(azetidin-3-ylidene)acetonitrile hydrochloride 

Downstream Products

• 1334302-63-4 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate 

Relevant articles and documents

PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR

The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.

JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).

PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR

This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.